Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Search results (1)

« Back to News

The latest news, stories and exciting findings from across the Oxford cancer research community

University's RadCam library highlighted in yellow

An image of the fungus Cordyceps sinensis. Cordycepin is derived from Cordyceps sinensis, which has been used in traditional Chinese medicine for hundreds of years to treat cancers and other inflammatory diseases. Thanks to this Oxford University-NuCana partnership, a new drug called NUC-7738 has been derived from Cordycepin and is now being tested in clinical trials.

Anti-cancer drug derived from fungus shows promise in clinical trials

6 October 2021

A new industry-academic partnership between the University of Oxford and biopharmaceutical company NuCana as found that chemotherapy drug NUC-7738, derived from a Himalayan fungus, has 40 times greater potency for killing cancer cells than its parent compound.